Was Einhorn Wrong or Early on Martin Marietta Materials?

Page 1 of 2

GREENLIGHT CAPITALBillionaire David Einhorn of Greenlight Capital is closely followed, possibly most closely when he gives public presentations at investor conferences. See Einhorn’s most recent stock picks. He famously recommended shorting Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR) in October 2011, before the stock began plummeting; he had also been a public critic and short seller of Lehman Brothers in late 2007 and 2008. Einhorn led his presentation at the mid-May Ira Sohn Conference with a short thesis on Martin Marietta Materials, Inc. (NYSE:MLM). The stock is up 22% since then, easily beating the market. The stock had been declining quite a bit in early May, so it might not be entirely fair to measure its performance from the conference date, but even if we use the beginning of May as our baseline Martin Marietta is up 11% against a flat market.

The core of Einhorn’s thesis was simple. The stock was trailing at a P/E of more than 30, implying that the market was expecting strong growth, but net income should actually be coming down as the construction materials company (providing products such as limestone, granite, sand, and gravel) lost the benefits of short term fiscal stimulus. Business has still been good however, and in the third quarter of the year Martin Marietta Materials, Inc. experienced an 18% increase in revenue compared to the same period in 2011. Earnings were up 28%. Net income was actually down in the first nine months of 2012 versus a year ago, but that is more than accounted for by an unusual amount of business development costs in the first half of this year.

Martin Marietta’s valuation does look high, however, and while we don’t have any information as to whether or not Einhorn is still short (short positions are not disclosed in 13F filings) it’s possible that Greenlight was merely early. The forward P/E is 28, and that incorporates high growth expectations on the sell side for 2013. Even over the longer term analyst consensus is for fairly low earnings in relation to the stock price, with a five-year PEG ratio of 4. There have been significant insider sales at Martin Marietta, and the most recent data shows that 18% of outstanding shares are held short.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!